Zobrazeno 51 - 60
of 80
pro vyhledávání: ''
Autor:
Do Hyoung Lim, Jung Han Kim, Seong Yoon Yi, Jun Ho Yi, Keon Woo Park, Soonil Lee, Hye Ran Lee, Jeeyun Lee
Publikováno v:
Melanoma research. 21(3)
Malignant melanoma, a neoplastic disorder produced by malignant transformation of the melanocyte, is considered to be resistant to chemotherapy. Dacarbazine is one of the standard chemotherapeutic agents in Korea. This study is designed to analyze tr
Autor:
Fa-Chyi Lee, Claire F. Verschraegen, Valerie Parks, Ian Rabinowitz, Sujana Movva, Aroop Mangalik
Publikováno v:
Melanoma research. 21(1)
This phase I study was carried out to evaluate the optimal dose of temozolomide in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Patients with advanced melanoma or small cell lung cancer that could benefit from t
Autor:
Gérard Guillet, Bernard Guillot, Bruno Sassolas, Jean Marc Tourani, Laurent Mourey, Christophe Bedane, E. Wierzbicka-Hainaut
Publikováno v:
Melanoma research. 20(2)
Temozolomide (TMZ) is a second-generation alkylating agent that has recently shown some efficacy in stage IV melanoma. The purpose of this study was to test the efficacy and safety of combination therapy with TMZ and cisplatin (CDDP) in patients with
Publikováno v:
Melanoma research. 19(2)
Isolated limb infusion (ILI) is a minimally invasive technique of delivering regional chemotherapy in patients with advanced melanoma or soft-tissue sarcoma of the limb. We report the final results of the first clinical trial of ILI in North America
Autor:
Laura, Ridolfi, Giammaria, Fiorentini, Michele, Guida, Maria, Michiara, Andrea, Freschi, Enrico, Aitini, Michela, Ballardini, Ettore, Bichisao, Ruggero, Ridolfi, E T, Menichetti
Publikováno v:
Melanoma research. 19(2)
The efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 biochemotherapy were evaluated in advanced melanoma patients. The schedule consisted of fotemustine (100 mg/m) and cisplatin (75 mg/m) intravenous on day 1, f
Autor:
Brigitte Coras, Eva-B. Bröcker, Klaus Neuber, Albrecht Reichle, Thomas Vogt, Anna Berand, Erwin Schultz, Reinhard Andreesen, Uwe Trefzer, Peter Terheyden, Michael Landthaler
Publikováno v:
Melanoma research. 17(6)
An angiostatic approach was used to assess the impact of anti-inflammatory therapy in combination with metronomic low-dose chemotherapy. A randomized multi-institutional phase II trial was designed to select metronomic chemotherapy (arm A: trofosfami
Publikováno v:
Melanoma research. 17(5)
A feasibility study was conducted to establish the safety and, to some extent, the effectiveness of a new approach of perioperative adjuvant biotherapy in patients with resected cutaneous melanoma. The candidates for this study included patients with
Publikováno v:
Melanoma research. 17(4)
Melanoma is a hypervascular tumor and angiogenesis plays a critical role in the development/progression of metastases. As various pathways are involved in tumor angiogenesis, a combination of agents with different antiangiogenesis activities is a rea
Autor:
Johan Hansson, Eva Månsson-Brahme, Bo Nilsson, Gunnar Wagenius, Boel Ragnarsson-Olding, Giuseppe Masucci
Publikováno v:
Karolinska Institutet
Temozolomide is a rapidly absorbed chemotherapeutic agent, achieving significant central nervous system penetration. Previous clinical trials suggested that temozolomide in sequence with low-dose recombinant human interleukin-2 might be an efficaciou
Autor:
Julio Rifà, Elena Filipovich, J. R. Germa-Lluch, Xavier Garcia del Muro, Margarita García, X. Perez, Manuel Valladares, Carmen Crespo, Alejandro Tres, Juan José López
Publikováno v:
Melanoma research. 16(4)
OBJECTIVE Temozolomide is a novel oral alkylating agent, active against metastatic melanoma. Combinations of chemotherapy and biological response modifiers have been associated with increased antitumour activity. A multicentre phase II study was perf